A recent retrospective study of 740 patients conducted by the Hodgkin Lymphoma Registry in British Columbia revealed a narrower distribution between the high and low IPS; however, differences in the 5-year FFP ranging between 62% for patients with IPS>4 and 88% for patients with IPS=0 ( P< 0.001) and in the 5-year OS ranging between 67% and 98% ( P< 0.001) were still highly significant. 17 In a recent Eastern Cooperative Oncology Group study (ECOG 24963) of patients with advanced disease treated with either ABVD or Stanford V, the 5-year FFP was 82%, 74%, 63% for patients with IPS 0–2, 3–4, 5–7, respectively. 18 Federico et al. demonstrated an inferior outcome for patients with I
1
—
—